84
Current guidelines recommend the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with rigorous lifestyle modification as well as optimised therapies for cardiometabolic comorbidities as first-line therapy,1 whereas specific pharmacological treatment for non-cirrhotic MASH with fibrosis might include resmetirom (a thyroid hormone receptor β-agonist approved in the USA and Europe)2 and semaglutide (GLP-1 receptor agonist approved in the USA),3 which are both shown to improve liver histology and metabolic parameters.
